Pivotal phase III study of RHB-104 for the treatment of nontuberculous mycobacteria (NTM) infections
Phase of Trial: Phase III
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Clarithromycin/clofazimine/rifabutin (Primary)
- Indications Mycobacterial infections
- Focus Registrational; Therapeutic Use
- Sponsors RedHill Biopharma
- 23 Oct 2017 According to a RedHill Biopharma media release, this trial is expected to begin in 1H 2018.
- 31 Aug 2017 New trial record
- 10 Aug 2017 According to a RedHill Biopharma media release, this study is planned to begin in in the first quarter of 2018.